Vascular Disease Clinical Trial
Official title:
Bone Metabolism and Cardiovascular Risk After Kidney Transplant in Adult Patients
Bone disorder is a significant problem in chronic kidney disease (CKD), becoming almost
universal in stage 5 CKD patients. Besides the healthcare costs, bone disorder is associated
with life-threatening complications, including fractures and cardiovascular (CV) events.
Kidney transplantation provides circa 68% decrease in mortality and improves co-morbidity.
Still, bone disease persists after transplantation.
The investigators hypothesize that bone-derived hormones can induce CV events in kidney
transplanted patients. Therefore, early evaluation of the bone health is recommended, and
prevention of its complications is required. Bone biopsy, an invasive and expensive method,
is the gold standard for bone disorders diagnosis. Therefore, non-invasive predictors for
bone disease are necessary. Classical biochemical markers of bone formation and resorption
have shown a low sensitivity and low specificity. New markers, as fibroblast growth factor 23
(FGF23), and its cofactor klotho, and sclerostin are promising new markers for predicting
CKD-associated bone and CV disease after transplantation.
This study assesses the phenotype of bone disease after transplantation (given by bone
histology) and its correlation with serum FGF23, klotho and sclerostin, in order to evaluate
its performance predicting CKD-associated bone and CV disease.
BACKGROUND. Chronic kidney disease (CKD) affects millions of people worldwide. Cardiovascular
(CV) events cause more than 50% of the mortality risk in CKD patients, and the relative
excess mortality is observed in younger patients, below 45 years of age. Decreased renal
function led to changes in biochemical parameters (calcium, phosphorus, PTH and vitamin D
levels) and disturbed mineral metabolism, which translates into different bone disorders
(related to bone turnover, mineralization, and volume) and all these are associated with
extra-skeletal calcifications. Bone disease at any stage of CKD is associated with CV
morbidity. This cross-talk between bone and vessels constitute a systemic syndrome known as
CKD-mineral and bone disorder (CKD-MBD), that is thought to be one of the major
non-traditional risk factors for the extremely high rate mortality observed in this disease.
CKD-MBD is classified into four major histological groups (in terms of turnover,
mineralization and volume): hyperparathyroid bone disease (high turnover disease, with normal
mineralization and variable volume); adynamic bone disease (low turnover disease, with normal
mineralization and decreased bone volume); osteomalacia (low turnover disease, with reduced
mineralization and with normal or high bone volume); and mixed renal osteodystrophy (reduced
mineralization with or without increased bone formation).
Kidney transplantation is the treatment of choice for established stage 5 CKD. Even with
correction of uremia, post-transplant MBD is frequent and reflects the pre-existing CKD-MBD,
the effects of renal dysfunction after transplantation, and the effects and consequences of
immunosuppression. Transplanted patients with CKD-MBD have reduced quality of life and
require medical assistance for bone pain, fractures and CV events. Indeed, cardiovascular
disease remains the leading cause of death after renal transplantation, still doubling risk
of the general population.
The gold standard for the diagnosis of CKD-associated bone disease is bone biopsy, an
expensive and invasive procedure. Non-invasive markers of bone disease presently lack
sufficient specificity and sensitivity to allow the differential diagnosis of renal
osteodystrophy. New biomarkers are needed and, osteocyte-derived factors, as FGF23 and
sclerostin, are promising answers.
FGF23 acts as a phosphaturic hormone, a suppressor of vitamin D and has some non-consensual
effect on parathyroid hormone (PTH). FGF23 has a specific receptor but needs a co-factor,
klotho protein, to perform the majority of its functions. Serum klotho levels in CKD are low,
influencing the resistance to FGF23 activity. What happens in transplanted patients is not
yet totally understood; some studies pointed out for endothelial dysfunction and
cardiovascular disease mediated by these factors in the transplant setting. Besides, graft
loss and mortality were related with high serum levels of FGF23 and with bone mineral density
loss but their relation with histological bone disease is unknown.
Sclerostin is a glycoprotein product of the SOST gene in osteocytes and acts as a negative
regulator of bone metabolism. Various observations have shown that CKD patients have high
sclerostin serum levels, thus its potential role in renal osteodystrophy. The correlation
between serum levels of sclerostin and histomorphometric parameters of bone turnover,
osteoblast number and function in renal transplanted patients is not yet known. The impact of
high sclerostin levels on CV disease and mortality is yet to be determined.
Studies relating sclerostin levels with CV mortality in dialysis patients are inconsistent.
Studies in renal transplanted patients are lacking.
AIMS. The investigators will study the relationship of the new osteocyte-derived biomarkers
of bone disease, FGF23 (and klotho) and sclerostin, with bone histologic changes and CV
events at baseline and one year after transplantation. If an association is to be found, the
performance of the biomarkers as predictors of CKD-MBD will be determined. Non-contrast CT
will allow us to validate Adragão score in a population of renal transplants, as this score
is only validated for dialysis patients. We will study possible correlations between coronary
artery calcification score and demographic characteristics of patients; laboratorial levels
of FGF23, klotho, esclerostin, PTH, calcium, phosphorus, calcium x phosphorus, magnesium,
LDL-colestherol, and albumin (both at T0 and T1), bone turnover, mineralization and volume
(both at T0 and T1), and DXA results at 1 year. From these findings, we will try to discover
potential new risk factors for vascular calcifications in renal transplant patients and
potential pathophysiological mechanisms for this phenomenon.
METHODS. Prospective cohort study of a convenience, consecutive sample of de novo renal
transplanted patients.
At recruitment, data will be collected on aetiology of CKD, presence of diabetes,
hypertension, hyperparathyroidism, hepatitis virus, ovulation status for woman (menopause or
not), active pre-transplant medication (with emphasis in vitamin D analogues, calcimimetics,
and phosphate binders), echocardiography (M mode and 2D), Teresa Adragão score of vascular
calcifications (hands and pelvis x-rays), HLA phenotype and mismatches, donor data (age,
gender, cause of death), cold ischemia time.
Patients will be followed-up for 1 year, during which data will be recorded on
immunosuppressive regimens (cumulative doses), CV events (myocardial infarction, congestive
heart failure, arrhythmia), fractures, rejection episodes, graft loss (and its cause), and
death (CV [fatal myocardial infarction, sudden death and fatal congestive heart failure],
infection, malignancy or other). At the end of follow-up, echocardiogram (M mode and 2D) and
scoring of vascular calcifications will be performed.
Serum creatinine, urea, ionogram, uric acid, calcium, phosphorus, magnesium, and bone
alcaline phosphatase will be assessed using standard methods. PTH will be measured by
immuno-chemiluminescence using a second-generation assay (Immulite 2000; Siemens Medical
Solutions Diagnostics, Los Angels, CA). Vitamin D [25(OH)D and 1,25(OH)2D] will be measured
with radioimmunoassay provided by IDS (Boldon, UK).
Two bone biopsies are proposed to each patient (just before the renal transplantation
procedure, already on general anaesthesia, and circa 12 months after transplantation, with
local anaesthesia). Bone biopsies will be made using a 7G trocar (Osteobell T), by manual
puncture. After processing the bone fragment (fixation, dehydration and methylmethacrylate
impregnation), routine staining will be used: von Kossa, Goldner trichrome, acid phosphatase
(selective staining of osteoclasts), and Perls. Cortical bone will be evaluated separately
from trabecular bone. Cortical bone volume and cortical thickness will be measured. Bone
biopsies will be described for: bone remodelling and degree of cellular activation (specific
score); efficacy of mineralization; quantification of possible metal deposits. In order to
evaluate the rate of bone formation and rate of mineral deposition, the patient will be
prescribed tetracycline hydrochloride, 500mg, 12/12 hours for three days, one month and one
week before the 2nd bone biopsy or, in the case of live donor transplantation, before the 1st
and 2nd bone biopsy.
At the same time point of the bone biopsies [at day 0 (pre-transplant) and nearly at month
12] serum levels of FGF23, and its cofactor Klotho, and sclerostin will be measured in the
immunology lab of our hospital, according to the manufacturer's instructions. C-terminal
FGF23 will be measured by sandwich ELISA (Immunotopics, San Clement, CA). Alfa-klotho will be
measured by ELISA (IBL America, MN, USA). Sclerostin will be assessed by TECO Sclerostin EIA
kit, which is a 96-well immune-capture ELISA (Sissach, Switzerland).
Comparisons between bone biopsies before and after transplantation will be assessed by paired
t-test (if comparing scores) or by paired McNemar's test (after switching scores into
categorical variables). Multivariable analysis adjusted for age, gender, diabetes,
immunosuppressive regiments and/or its cumulative doses, and renal function will be performed
to identify independent risk factors for the disease type and severity. In females, menopause
will be considered as an effect modifier of bone volume.
Comparisons between FGF23, Klotho and sclerostin pre and post-transplant will be made by
paired t-test, assuming normal distribution. Associations between FGF23, Klotho and
sclerostin levels with demographic data and biochemical parameters in the two time-points
will also be accessed with t-test, with Pearson test and linear regression, whenever
applicable. A multivariable analysis will be executed to control for confounders (age,
gender, diabetes, PTH, renal function, immunosuppressive regiments). Associations between
FGF23, Klotho and sclerostin with bone turnover, mineralization and volume will be explored
with regression models. The potential effects of FGF23 or sclerostin with CV health will be
explored using regression models.
we are proposing to study as well vascular calcifications in post-transplant renal patients.
For this, we will evaluate vascular calcifications by two different methods:
- Plain X-ray of the pelvis and hands for evaluation of vascular calcifications through
Teresa Adragão score at day 0 and nearly at 12 months.
- Non-contrast CT in a low-radiation exposure technique, quantified using the Agatston
method(26), performed nearly at 15 months after the renal transplant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
Completed |
NCT02542267 -
In-Stent Restenosis Post-Approval Study
|
N/A | |
Completed |
NCT01608035 -
Sciatic Perineural Versus Stump Catheter for Below Knee Amputation
|
Phase 0 | |
Completed |
NCT00987181 -
Non-Contact Measurement of Aortic Compliance
|
N/A | |
Completed |
NCT00865124 -
Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
|
N/A | |
Completed |
NCT00759681 -
ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial
|
Phase 3 | |
Completed |
NCT01182428 -
XIENCE V: SPIRIT WOMEN Sub-study
|
Phase 4 | |
Completed |
NCT00633659 -
Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia
|
Phase 2 | |
Completed |
NCT00341562 -
Genomics of In-Stent Restenosis
|
N/A | |
Completed |
NCT00110604 -
The Effect of Folic Acid on Atherosclerosis, Cognitive Performance and Hearing
|
N/A | |
Completed |
NCT01355406 -
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
|
N/A | |
Not yet recruiting |
NCT02843854 -
Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms
|
Phase 1 | |
Completed |
NCT01229358 -
Clinical Trial of a Silver Eluting Dressing System
|
Phase 4 | |
Completed |
NCT01205789 -
EXCEL Clinical Trial (Universal Registry)
|
N/A | |
Completed |
NCT01221610 -
BIOLUX P-I First in Man Study
|
N/A | |
Recruiting |
NCT01358630 -
Vascular and Periodontal Disease - Microbial, Genetic and Histological Causalities
|
N/A | |
Completed |
NCT00805831 -
Safety and Efficacy of Using HDH Device and Method - a Novel Sutureless Vascular Anastomosis
|
N/A | |
Completed |
NCT00782015 -
Effects of Almonds on Vascular Reactivity in Patients With Coronary Artery Disease
|
N/A | |
Withdrawn |
NCT00334724 -
Home Blood Pressure-guided Antihypertensive Intervention for Elderly (HBP-GUIDE) Study
|
Phase 4 | |
Completed |
NCT02562781 -
Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications?
|
Phase 3 |